NEW YORK, NY – October 1, 2021 – Woolsey Pharmaceuticals announced today that it completed a second round of financing of $19.7 million. Proceeds will fund operations through the completion of Phase 2a clinical studies of BRAVYL for Wandering in Dementia, Progression Supranuclear Palsy, Corticobasal Syndrome, and Amyotrophic Lateral Sclerosis.
The Company also announced the appointment Rich Nelson as a board observer. Rich is the founder of Nelstone Ventures, a venture capital company, and sits on the board of VtV Therapeutics.
Rich joins the company’s two outside board members, David Epstein, previously the CEO of Novartis Pharmaceuticals, and Claude Piché, founder and CEO of Locemia Solutions, a privately held, specialty pharmaceutical company acquired by Lilly, as well as existing board observer, Nataly Langner, manager of the Langner Family investments.
Woolsey Pharmaceuticals is also pleased to announce the appointment of Sabrina Williams as Director of Clinical and Regulatory Affairs. Sabrina has managed the overall drug development activities for numerous products in both early and late stages of development, including regulatory approvals. Sabrina received her BS in Pharmaceuticals Science at the Massachusetts College of Pharmacy and Allied Health.
ABOUT WOOLSEY PHARMACEUTICALS
New York-based Woolsey Pharmaceuticals is focused on the treatment of rare, neurodegenerative diseases. The company’s lead product is BRAVYL (oral fasudil).